Alternative Regulatory Pathway for Generic Inhaled Drugs
Uncover the pathways for generic OINDP and the challenges and solutions in the pharmaceutical regulatory landscape for inhalation drug products.
Physiologically-based Pharmacokinetic Models (PBPK) for OINDPs
Aptar Pharma discusses Physiologically based PK models for OINDPs.
Why it is time to ‘Think Different’ about nasal delivery of biologics.
Nanopharm discusses the challenges and benefits of delivering biologics via the nasal route.
Nasal Drug Development, Trends and Challenges with Nasal Formulations
Nanopharm explores the current trends and technical challenges in nasal drug product development, focusing on formulation.
Nanopharm’s Innovations in Nasal Drug Delivery of Biologics
Discover Nanopharm’s pioneering work in nasal drug delivery of biologics. Learn how their research is shaping drug development against SARS-CoV-2.
Conversations with Dr Julie Suman, on Nasal Drug Delivery: Current trends, technical challenges and opportunities for therapeutic innovation
Aptar Pharma present data on the challenges and opportunities for Nasal drug delivery.
Nasal Drug Development, Trends and Challenges with Nasal Formulations
Nanopharm explores the current trends and technical challenges in nasal drug product development, focusing on formulation.
Nanopharm: cGMP Drug Development in OINDP
Nanopharm expands with cGMP facilities for advanced drug development in OINDP. Specializing in biologics characterization and particle engineering.
Nanopharm’s Nasal Spray for SARS-CoV-2 Antibody Treatment
Discover Nanopharm’s innovative nasal spray for SARS-CoV-2. Learn how this prophylactic treatment effectively delivers antibodies for maximum protection.
Nanopharm & Leyden – OINDP Intranasal Sprays vs. Respiratory Viruses
Nanopharm & Leyden Labs collaborate on intranasal sprays for broad protection against respiratory viruses. Focused on OINDP drug development.
